Trial | NCT00825721  Report issue

Title

Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract
A Randomized, Placebo-Controlled, Single-Masked, Dose-Ranging Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataracts

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    n-acetylcarnosine ...

  • Study Participants

    81
This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract
Study Started
Nov 30
2007
Primary Completion
Aug 31
2009
Anticipated
Study Completion
Sep 30
2009
Anticipated
Last Update
Jan 21
2009
Estimate

Drug LiquiTears

4 drops applied daily for 360 days

Drug C-KAD Ophthalmic Solution

4 drops applied daily for 360 days

Drug C-KAD Ophthalmic Solution

4 drops applied daily for 360 days

Drug C-KAD Ophthalmic Solution

4 drops applied daily for 360 days

1.3% (low dose) Active Comparator

2% (medium dose) Active Comparator

2.6% (high dose) Active Comparator

Placebo Placebo Comparator

Criteria 

Inclusion Criteria:

Presence of nuclear sclerosis cataract
BCDVA within the range of 20/40 and 20/80

Exclusion Criteria:

Any other clinical condition in the eye that may compromise vision
Presence or history of glaucoma
Presence or history of diabetes
Use of eyedrops
Use of steroids
No Results Posted